Viking Therapeutics (VKTX) Assets Average (2015 - 2026)

Viking Therapeutics (VKTX) has 12 years of Assets Average data on file, last reported at $662.0 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 25.42% year-over-year to $662.0 million; the trailing twelve-month figure through Mar 2026 stood at $662.0 million (down 25.42% YoY), and the FY2025 full-year result was $812.0 million, up 27.2% from the prior year.
• Assets Average slipped to $662.0 million in Q1 2026, from $727.6 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $957.2 million in Q2 2024 to a low of $159.7 million in Q1 2023.
• A 5-year average of $549.1 million and a median of $662.0 million in 2026 frame the typical range for Assets Average.
• Across the five-year window, Assets Average surged 318.26% in 2024 and decreased 25.42% in 2026, its largest moves.
• Tracing VKTX's Assets Average over 5 years: stood at $167.6 million in 2022, then soared by 124.08% to $375.6 million in 2023, then jumped by 145.78% to $923.1 million in 2024, then decreased by 21.18% to $727.6 million in 2025, then fell by 9.01% to $662.0 million in 2026.
• Business Quant data shows VKTX's Assets Average at $662.0 million in Q1 2026, $727.6 million in Q4 2025, and $783.6 million in Q3 2025.